Effect of flunarizine combined with carbamazepine in the treatment of migraine
	    		
		   		
		   			
		   		
	    	
    	 
    	10.3760/cma.j.issn.1008-6706.2020.19.018
   		
        
        	
        		- VernacularTitle:氟桂利嗪联合卡马西平治疗偏头痛的效果观察
 
        	
        	
        	
        		- Author:
	        		
		        		
		        		
			        		Yeqin LI
			        		
			        		
			        		
			        			1
			        			
			        		
			        		
			        		
			        		
			        		;
		        		
		        		
		        		
			        		Kewen XU
			        		
			        		;
		        		
		        		
		        		
			        		Jing WENG
			        		
			        		
		        		
		        		
		        		
		        		
		        			
			        		
			        		Author Information
			        		
		        		
		        		
			        		
			        		
			        			1. 浙江省,余姚市人民医院神经内科 315400
			        		
		        		
	        		
        		 
        	
        	
        	
        	
            
            
            	- From:
	            		
	            			Chinese Journal of Primary Medicine and Pharmacy
	            		
	            		 2020;27(19):2384-2388
	            	
            	
 
            
            
            	- CountryChina
 
            
            
            	- Language:Chinese
 
            
            
            	- 
		        	Abstract:
			       	
			       		
				        
				        	Objective:To explore the effect and safety of flunarizine combined with carbamazepine in the treatment of migraine.Methods:From January 2018 to December 2018, 88 migraine patients treated in Yuyao People's Hospital were divided into control group ( n=44) and observation group ( n=44) according to different treatment methods.The control group was given flunarizine, and the observation group was treated with flunarizine combined with carbamazepine.The clinical efficacy and the incidence of adverse reactions were compared between the two groups through evaluation of the SF-36 scale score before and after treatment and the main cerebral arterial blood flow velocity. Results:The total effective rate in the observation group was significantly higher than that in the control group (90.91% vs.72.73%, χ 2=5.437, P<0.05), and the incidence of adverse reactions had no statistically significant difference between the two groups (15.91% vs.11.36%, P>0.05). The scores of the SF-36 scale in the observation group after treatment were significantly higher than those in the control group [PF: (86.15±8.24)points vs.(93.78±9.73)points; RP: (67.15±12.96)points vs.(87.93±13.78)points; BP: (59.59±15.75)points vs.(73.25±18.34)points; GH: (58.92±14.83)points vs.(69.12±17.93)points; VT: (64.98±15.45)points vs.(72.48±16.78)points; SF: (78.62±14.91)points vs.(87.26±15.72)points; RE: (60.25±18.45)points vs.(69.12±15.72)points; MH: (74.91±16.45)points vs.(87.12±17.93)points], the cerebral arterial blood flow velocity was significantly lower than the control group [ACA: (57.12±8.94)cm/s vs.(52.73±9.02)cm/s; MCA: (75.82±11.92)cm/s vs.(63.09±11.25)cm/s; PCA: (49.87±10.64)cm/s vs.(45.10±9.25)cm/s; VA: (46.20±4.02)cm/s vs.(44.12±4.03)cm/s; BA: (50.10±6.95)cm/s vs.(46.52±7.21)cm/s] (PF: t=3.969, RP: t=7.287; BP: t=3.748; GH: t=2.908; VT: t=2.181; SF: t=2.645; RE: t=2.427; MH: t=3.329; ACA: t=2.293; MCA: t=5.152; PCA: t=2.244; VA: t=2.424; BA: t=2.371, P<0.05). Conclusion:Flunarizine combined with carbamazepine can significantly improve the treatment effect of migraine, improve the quality of life and cerebral arterial blood flow velocity of patients, and has high safety.